JP2024509385A5 - - Google Patents
Info
- Publication number
- JP2024509385A5 JP2024509385A5 JP2023550178A JP2023550178A JP2024509385A5 JP 2024509385 A5 JP2024509385 A5 JP 2024509385A5 JP 2023550178 A JP2023550178 A JP 2023550178A JP 2023550178 A JP2023550178 A JP 2023550178A JP 2024509385 A5 JP2024509385 A5 JP 2024509385A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ovarian cancer
- cancer cells
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156715P | 2021-03-04 | 2021-03-04 | |
| US63/156,715 | 2021-03-04 | ||
| PCT/US2022/070961 WO2022187851A1 (en) | 2021-03-04 | 2022-03-04 | Actinohivin variant polypeptides and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509385A JP2024509385A (ja) | 2024-03-01 |
| JP2024509385A5 true JP2024509385A5 (enExample) | 2025-01-06 |
Family
ID=83155364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550178A Pending JP2024509385A (ja) | 2021-03-04 | 2022-03-04 | アクチノヒビンバリアントポリペプチド及び関連方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240123026A1 (enExample) |
| EP (1) | EP4301389A4 (enExample) |
| JP (1) | JP2024509385A (enExample) |
| CN (1) | CN117098545A (enExample) |
| AU (1) | AU2022229597A1 (enExample) |
| CA (1) | CA3210629A1 (enExample) |
| IL (1) | IL305259A (enExample) |
| MX (1) | MX2023010183A (enExample) |
| WO (1) | WO2022187851A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018148541A1 (en) | 2017-02-10 | 2018-08-16 | University Of Louisville Research Foundation, Inc. | Actinohivin variant polypeptides and related methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012071492A1 (en) * | 2010-11-23 | 2012-05-31 | Georgia Tech Research Corporation | Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells |
| EP3194973A1 (en) * | 2014-09-17 | 2017-07-26 | Institut Curie | Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor |
| WO2018148541A1 (en) * | 2017-02-10 | 2018-08-16 | University Of Louisville Research Foundation, Inc. | Actinohivin variant polypeptides and related methods |
-
2022
- 2022-03-04 JP JP2023550178A patent/JP2024509385A/ja active Pending
- 2022-03-04 IL IL305259A patent/IL305259A/en unknown
- 2022-03-04 WO PCT/US2022/070961 patent/WO2022187851A1/en not_active Ceased
- 2022-03-04 CN CN202280015649.3A patent/CN117098545A/zh active Pending
- 2022-03-04 CA CA3210629A patent/CA3210629A1/en active Pending
- 2022-03-04 EP EP22764272.5A patent/EP4301389A4/en active Pending
- 2022-03-04 MX MX2023010183A patent/MX2023010183A/es unknown
- 2022-03-04 US US18/277,684 patent/US20240123026A1/en active Pending
- 2022-03-04 AU AU2022229597A patent/AU2022229597A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517236A5 (enExample) | ||
| JP2022536511A (ja) | 癌の処置のための併用療法での活性化可能抗ｐｄｌ１抗体および抗ｃｔｌａ－４抗体の使用 | |
| JP2023516936A5 (enExample) | ||
| TWI894144B (zh) | 藉由投予il-33拮抗劑治療或預防哮喘之方法 | |
| JP2017512193A (ja) | Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法 | |
| JP2024001125A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP7357646B2 (ja) | 乾癬の治療のための組成物及び方法 | |
| CN107614530A (zh) | 用于多发性骨髓瘤（mm）的治疗 | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2024016209A5 (enExample) | ||
| CN112969718A (zh) | Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途 | |
| EP4023679A1 (en) | Fusion protein targeting pd-l1 and tgf-beta and use thereof | |
| CN115698059A (zh) | 使用抗bet v 1抗体治疗过敏的方法 | |
| JP2023507795A5 (enExample) | ||
| US20250263471A1 (en) | Methods of treating allergy using anti-bet v 1 antibodies | |
| CN119587691A (zh) | 抗her2抗体药物偶联物联合抗her2抗体治疗肿瘤 | |
| JP2022530063A (ja) | 抗体製剤 | |
| JP2026503435A (ja) | 乳癌を治療するための抗ｈｅｒ２抗体薬物複合体 | |
| CN119677533A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| CN115814076A (zh) | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| HK40076695A (en) | FUSION PROTEIN TARGETING PD-L1 AND TGF-β AND USE THEREOF |